Kline Launches Drug Switch Forecasts

US MR agency Kline & Company has launched interactive forecasting models to help clients anticipate and plan for changes in the pharma industry. The FutureView models aim to forecast the likelihood and impact of prescription-only drugs being granted over-the-counter (OTC) status.

Subscribers to two existing Kline MR services will be granted access to the relevant FutureView models, which provide five-year forecasts at the manufacturer sales and retail sales levels, based on certain assumptions based on primary and secondary research. They can then modify the assumptions to see the impact this has. Assumptions cover population growth, market exclusivity, patent expiration, timing of switch, timing of private-label entry, compound annual growth rates, dosage, price per pill and patient compliance rates, among other factors.

Laura Mahecha, industry manager for the healthcare practice of Kline's research division, explains: 'We designed these tools to help companies to plan for future Rx-to-OTC switches, whether they are a company that is pursuing a switch or a competitor whose business will be affected by a future switch.'

Susan Babinsky, head of the company's healthcare consulting practice, adds: 'Our forecast models reflect over 15 years of analysis on Rx-to-OTC switches. This experience and historical data allow us to create very powerful forecast models. We also layer in consumer research and price modeling so we can provide very specific outcome assessments, including positioning and pricing strategy.'

Kline & Company provides research and consulting in the life sciences, consumer products, chemicals, and energy industries. The company's web site is at www.klinegroup.com.

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Kline & Company, Inc.
• All news